It is important that patients suffering from pernicious anaemia, the result of a vitamin B12 (cobalamin) deficiency, receive a prompt and appropriate diagnosis. Pernicious anaemia develops gradually, and can cause a range of symptoms, including fatigue, lethargy, feeling faint and headaches, which vary from patient to patient. Because of the gradual progression of the condition, the variety of symptoms, which are shared with a range of other conditions, diagnosis at early onset can be challenging.<\/p>
To support the diagnosis of pernicious anaemia, the British Committee for Standards in Haematology (BCSH) has published Guidelines for the diagnosis and treatment of Cobalamin and Folate disorders,<\/em> which sets out that cobalamin status is the recommended first line diagnostic test. However, the guidance states that there is no gold standard test for the condition and makes it clear that the clinical picture of a patient is the most important factor in assessing the significance of the test results. This means clinicians should take into account all of the symptoms the patent is experiencing, their medical history, age and other relevant factors when considering the implications of a patient\u2019s cobalamin status. The BCSH guidance highlights the risk of neurological impairment if treatment is delayed.<\/p> It is important that patients suffering from pernicious anaemia, the result of a vitamin B12 (cobalamin) deficiency, receive a prompt and appropriate diagnosis. Pernicious anaemia develops gradually, and can cause a range of symptoms, including fatigue, lethargy, feeling faint and headaches, which vary from patient to patient. Because of the gradual progression of the condition, the variety of symptoms, which are shared with a range of other conditions, diagnosis at early onset can be challenging.<\/p> To support the diagnosis of pernicious anaemia, the British Committee for Standards in Haematology (BCSH) has published Guidelines for the diagnosis and treatment of Cobalamin and Folate disorders,<\/em> which sets out that cobalamin status is the recommended first line diagnostic test. However, the guidance states that there is no gold standard test for the condition and makes it clear that the clinical picture of a patient is the most important factor in assessing the significance of the test results. This means clinicians should take into account all of the symptoms the patent is experiencing, their medical history, age and other relevant factors when considering the implications of a patient\u2019s cobalamin status. The BCSH guidance highlights the risk of neurological impairment if treatment is delayed.<\/p> The Department does not hold information on the average cost to the taxpayer of training someone to become a doctor in the United Kingdom.<\/p> The Personal Social Services Research Unit at the University of Kent estimates within their report \u2018Unit Costs of Health and Social Care 2014\u2019, published March 2014, that the average cost in 2013/14 <\/ins> <\/p> <\/p> <\/p> <\/p> Timing for access to care or treatments for all NHS England service specifications or policies is based on an assessment of the evidence for clinical effectiveness, cost effectiveness and affordability.<\/ins><\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2015-07-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/385301/answer/previousversion/12907", "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
}
, "questionFirstAnswered" : [{"_value" : "2015-07-08T13:53:15.517Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-07-08T14:59:37.913Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hepatitis"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government why the national waiting time criterion for referral to hepatitis C treatment is 18 weeks whereas the national waiting time criterion for referral to specialist services for HIV treatment is two weeks.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1850", "label" : {"_value" : "Biography information for Baroness Masham of Ilton"}
}
, "tablingMemberPrinted" : [{"_value" : "Baroness Masham of Ilton"}
], "uin" : "HL784"}
, {"_about" : "http://data.parliament.uk/resources/348423", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/348423/answer", "answerText" : {"_value" : " On 1 June 2015, Monitor published Improving GP Services: Commissioners and Patient Choice<\/em>, which included the findings of a nationally representative survey conducted by Ipsos Mori.<\/p> <\/p> <\/p> <\/p> The report noted a high level of satisfaction with general practice overall. It found that 81% of patients were satisfied with their general practitioner (GP) practice, while only 10% were dissatisfied.<\/p> <\/p> <\/p> <\/p> Monitor\u2019s report found that, after location, patients most value the ease of getting an appointment when choosing a GP practice. In order to improve access for patients, the Government has invested £175 million over two years through the Prime Minister\u2019s GP Access Fund. This is testing improved and innovative access to GP services through longer opening hours, such as at evenings and weekends, but also different ways of accessing services, for example the use of Skype consultations. Altogether, there are now 57 schemes covering over 2,500 practices, meaning that over 18 million patients are expected to benefit from improved access and transformational change at local level by March 2016.<\/p> Additionally, the Primary Care Infrastructure Fund is investing £1 billion, including<\/ins> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2015-06-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/348423/answer/previousversion/5697", "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
}
, "questionFirstAnswered" : [{"_value" : "2015-06-17T13:19:17.147Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-06-19T11:00:07.59Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "General Practitioners"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the results of a survey on behalf of Monitor, which found that one in ten people are dissatisfied with their general practitioner surgery.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1796", "label" : {"_value" : "Biography information for Lord Taylor of Warwick"}
}
, "tablingMemberPrinted" : [{"_value" : "Lord Taylor of Warwick"}
], "uin" : "HL235"}
, {"_about" : "http://data.parliament.uk/resources/347943", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/347943/answer", "answerText" : {"_value" : " A total of 8,243 suspected adverse drug reaction (ADR) reports with human papilloma virus (HPV) vaccines have been reported to the Medicines and Healthcare products Regulatory Agency (MHRA), via the Yellow Card Scheme, up to 3 June 2015.<\/p> <\/p> <\/p> <\/p> To date, more than 8 million doses of HPV vaccine have been given across the United Kingdom as part of the routine immunisation programme. The MHRA does not hold data on age-specific vaccine usage, and therefore age-specific reporting rates cannot be calculated.<\/p> <\/p> <\/p> <\/p> It is important to note that a Yellow Card report is not proof of a side effect occurring, but a suspicion by the reporter that the vaccine may have been the cause. Yellow Card data cannot be used as a reliable indicator of the frequency of suspected ADRs to vaccines or medicines. The level of ADR reporting may fluctuate between given years due to a variety of reasons such as a medicine being new (reporting rates are generally higher when a product is first introduced), stimulated interest/publicity and variations in exposure to the medicine.<\/p> <\/p> <\/p> <\/p> The possible known side effects, and the frequency, are listed in the product information which is provided with the vaccines. The vast majority of the 8,243 ADRs relate to the known risks of vaccination that are well-described in the available product information. The proportion of suspected ADRs for HPV vaccines that were reported as serious (32%) is less than the proportion reported as serious for other routinely used vaccines (68% overall) during the same time period. The expected benefits in protecting against HPV-related mortality and disease outweigh the known side effects of HPV vaccine.<\/p> <\/p> <\/p> <\/p> The following table provides a breakdown of UK suspected spontaneous ADRs received via the Yellow Card Scheme in association with the HPV vaccine. The MHRA does not hold data on age-specific vaccine usage, and therefore age-specific reporting rates cannot be calculated.<\/p> <\/p> <\/p> <\/p> Vaccine Brand<\/p><\/td> Total number of reports<\/p><\/td> Number of serious reports (% of total)<\/p><\/td> Reporting rate per 1000 doses (serious reporting rates per 1000)<\/p><\/td><\/tr> Cervarix<\/p><\/td> 6,266<\/p><\/td> 1,768 (28%)<\/p><\/td> n/a **<\/ins> Gardasil<\/p><\/td> 1,471<\/p><\/td> 504 (34%)<\/p><\/td> n/a **<\/ins> HPV Brand unspecified<\/p><\/td> 507<\/p><\/td> 326 (64%)<\/p><\/td> n/a ** <\/ins> Total for Human Papilloma virus vaccines<\/p><\/td> *8,244<\/p><\/td> 2,598 (32%)<\/p><\/td> 1.03 (0.32)<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source:<\/em> MHRA sentinel database for adverse reactions.<\/p> <\/p> * It should be noted that the total number of reports received will not be equal to the totals in the table above as some reports of suspected adverse reactions may have included more than one vaccine.<\/p> **Updated UK-wide brand-specific usage data are not available to MHRA at the time of writing based on a minimum of 8 million combined doses of Cervarix and Gardasil administered across the UK to date.<\/ins><\/p> <\/p> <\/p> <\/p> <\/p><\/ins><\/p> <\/p> <\/p> <\/p> <\/p> <\/p> The seriousness criteria for ADR reporting were determined by a working group of the Council for International Organizations of Medical Sciences (CIOMS) and are defined as 6 possible categories which are explained on the Yellow Card. The MHRA asks reporters to select one of the following criteria by ticking the appropriate box on the Yellow Card: (1) patient died due to reaction; (2) life threatening; (3) resulted in hospitalisation or prolonged inpatient hospitalisation; (4) congenital abnormality; and (5) involved persistent or significant disability or incapacity; or (6) if the reaction was deemed medically significant. In addition to this, seriousness of reaction terms has also been defined by the MHRA in its medical dictionary. Therefore an ADR report can be serious because the reporter considers the reaction to be serious or because the reaction term itself is considered serious in the MHRA medical dictionary.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "dateOfAnswer" : {"_value" : "2015-06-16", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/347943/answer/previousversion/5462", "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
}
, "questionFirstAnswered" : [{"_value" : "2015-06-16T14:35:02.313Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-07-03T14:01:13.16Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government, to date, how many adverse reactions to (1) Cervarix, (2) Gardasil and (3) generic human papilloma virus vaccines have been reported to the Medicines and Healthcare products Regulatory Agency; for each category, how many of those reports are of serious adverse reactions; and what age-specific rate those figures represent.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
}
, "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
], "uin" : "HL229"}
, {"_about" : "http://data.parliament.uk/resources/224722", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/224722/answer", "answerText" : {"_value" : " The Department holds records of the total capital allocated to the respective recipient bodies as a result of the transfer of Mid-Staffordshire NHS Foundation Trust services but does not have details of the breakdown by individual hospital site.<\/p> <\/p> <\/p> <\/p> The capital provided to date is as follows:<\/p> <\/p> <\/p> <\/p> The Royal Wolverhampton NHS Trust<\/p><\/td> £12,109,000<\/p><\/td><\/tr> University Hospitals of North Midlands NHS Trust<\/p><\/td> £12,153,000<\/p><\/td><\/tr> Walsall Healthcare NHS Trust<\/p><\/td> £4,000,000<\/p><\/td><\/tr> Grand Total<\/p><\/td> £28,262,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Revenue funding provided to date is set out in the following table:<\/p> <\/p> <\/p> <\/p> University Hospitals of North Midlands NHS Trust<\/ins><\/p> <\/p><\/td> £32,420,000<\/p><\/td><\/tr> The Royal Wolverhampton NHS Trust<\/ins><\/p><\/td> £5,480,000<\/p><\/td><\/tr> Grand Total<\/p><\/td> £37,900,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The amount of public dividend capital issued to the Trust by the Department is as follows:<\/p> <\/p> <\/p> <\/p> 2009/10<\/p><\/td> £214,000<\/p><\/td><\/tr> 2010/11<\/p><\/td> £0<\/p><\/td><\/tr> 2011/12<\/p><\/td> £21,000,000<\/p><\/td><\/tr> 2012/13<\/p><\/td> £21,385,000<\/p><\/td><\/tr> 2013/14<\/p><\/td> £30,397,000<\/p><\/td><\/tr> 2014/15<\/p><\/td> £64,425,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The Department does not hold central records of non-tariff payments made by local commissioning bodies to NHS providers.<\/p> <\/p> <\/p> <\/p> The work of the trust special administrators (TSAs) to secure safe and sustainable services at Mid Staffordshire NHS Trust cost Monitor almost £19.5 million, including VAT, over 18 months.<\/p> <\/p> <\/p> <\/p> The first phase of trust special administration cost £9 million, including expenses and VAT. During this phase there was a team of up to 30 members of staff who carried out three core tasks - to help to run the Trust, to design the future of services provided at Stafford and Cannock hospitals, and to run a large public consultation involving thousands of responses and a series of public meetings.<\/p> <\/p> <\/p> <\/p> The second phase cost £10.5 million, including expenses and VAT. We are informed by Monitor that this second phase included a team of up to 50 people, which was required to continue to help run the hospital and implement the TSA\u2019s recommendations.<\/p> <\/p> <\/p> <\/p> We are also informed by Monitor that trust special administration at Mid-Staffordshire NHS Trust amounted to the rounded figure of 10,900 person-days for teams working on both phases of the process.<\/p> <\/p> <\/p> <\/p> In the table below, expenses incurred during the TSA process are split by the two phases of the TSA and totals are also provided. These expenses include:<\/p> <\/p> <\/p> <\/p> (a) accommodation;<\/p> <\/p> (b) travel (car, taxi and train);<\/p> <\/p> (c) subsistence; and<\/p> <\/p> (d) other expenses incurred; and what other costs to the TSA were incurred<\/p> <\/p> <\/p> <\/p> Breakdown of expenses, these exclude VAT:<\/p> <\/p> <\/p> <\/p> TSA1<\/p><\/td> TSA2<\/p><\/td> Total<\/p><\/td><\/tr> Accommodation<\/p><\/td> £82,242.89<\/p><\/td> £170,622.67<\/p><\/td> £252,865.56<\/p><\/td><\/tr> Travel<\/p><\/td> £144,122.38<\/p><\/td> £226,600.29<\/p><\/td> £370,722.67<\/p><\/td><\/tr> Subsistence<\/p><\/td> £16,171.73<\/p><\/td> £43,176.88<\/p><\/td> £59,348.61<\/p><\/td><\/tr> Other (incidentals such as printing, room hire and meeting refreshments)<\/p><\/td> £1,939.11<\/p><\/td> £3052.73<\/p><\/td> £4991.84<\/p><\/td><\/tr> Total<\/p><\/td> £244,476.11<\/p><\/td> £443,452.57<\/p><\/td> £687,928.68<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2015-03-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/224722/answer/previousversion/49060", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
}
, "questionFirstAnswered" : [{"_value" : "2015-03-10T17:13:10.567Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-03-17T16:58:22.383Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-03-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mid Staffordshire NHS Foundation Trust"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what (a) public dividend capital and (b) other non-tariff payments have been made to the Mid-Stafforshire NHS Foundation Trust in (i) 2009-10, (ii) 2010-11, (iii) 2011-12, (iv) 2012-13, (v) 2013-14 and (vi) 2014-15 to date.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"}
}
, "tablingMemberConstituency" : {"_value" : "Stafford"}
, "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"}
], "uin" : "225961"}
, {"_about" : "http://data.parliament.uk/resources/224723", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/224723/answer", "answerText" : {"_value" : " The Department holds records of the total capital allocated to the respective recipient bodies as a result of the transfer of Mid-Staffordshire NHS Foundation Trust services but does not have details of the breakdown by individual hospital site.<\/p> <\/p> <\/p> <\/p> The capital provided to date is as follows:<\/p> <\/p> <\/p> <\/p> The Royal Wolverhampton NHS Trust<\/p><\/td> £12,109,000<\/p><\/td><\/tr> University Hospitals of North Midlands NHS Trust<\/p><\/td> £12,153,000<\/p><\/td><\/tr> Walsall Healthcare NHS Trust<\/p><\/td> £4,000,000<\/p><\/td><\/tr> Grand Total<\/p><\/td> £28,262,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Revenue funding provided to date is set out in the following table:<\/p> <\/p> <\/p> <\/p> University Hospitals of North Midlands NHS Trust<\/ins><\/p><\/td> £32,420,000<\/p><\/td><\/tr> The Royal Wolverhampton NHS Trust<\/ins><\/p><\/td> £5,480,000<\/p><\/td><\/tr> Grand Total<\/p><\/td> £37,900,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The amount of public dividend capital issued to the Trust by the Department is as follows:<\/p> <\/p> <\/p> <\/p> 2009/10<\/p><\/td> £214,000<\/p><\/td><\/tr> 2010/11<\/p><\/td> £0<\/p><\/td><\/tr> 2011/12<\/p><\/td> £21,000,000<\/p><\/td><\/tr> 2012/13<\/p><\/td> £21,385,000<\/p><\/td><\/tr> 2013/14<\/p><\/td> £30,397,000<\/p><\/td><\/tr> 2014/15<\/p><\/td> £64,425,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The Department does not hold central records of non-tariff payments made by local commissioning bodies to NHS providers.<\/p> <\/p> <\/p> <\/p> The work of the trust special administrators (TSAs) to secure safe and sustainable services at Mid Staffordshire NHS Trust cost Monitor almost £19.5 million, including VAT, over 18 months.<\/p> <\/p> <\/p> <\/p> The first phase of trust special administration cost £9 million, including expenses and VAT. During this phase there was a team of up to 30 members of staff who carried out three core tasks - to help to run the Trust, to design the future of services provided at Stafford and Cannock hospitals, and to run a large public consultation involving thousands of responses and a series of public meetings.<\/p> <\/p> <\/p> <\/p> The second phase cost £10.5 million, including expenses and VAT. We are informed by Monitor that this second phase included a team of up to 50 people, which was required to continue to help run the hospital and implement the TSA\u2019s recommendations.<\/p> <\/p> <\/p> <\/p> We are also informed by Monitor that trust special administration at Mid-Staffordshire NHS Trust amounted to the rounded figure of 10,900 person-days for teams working on both phases of the process.<\/p> <\/p> <\/p> <\/p> In the table below, expenses incurred during the TSA process are split by the two phases of the TSA and totals are also provided. These expenses include:<\/p> <\/p> <\/p> <\/p> (a) accommodation;<\/p> <\/p> (b) travel (car, taxi and train);<\/p> <\/p> (c) subsistence; and<\/p> <\/p> (d) other expenses incurred; and what other costs to the TSA were incurred<\/p> <\/p> <\/p> <\/p> Breakdown of expenses, these exclude VAT:<\/p> <\/p> <\/p> <\/p> TSA1<\/p><\/td> TSA2<\/p><\/td> Total<\/p><\/td><\/tr> Accommodation<\/p><\/td> £82,242.89<\/p><\/td> £170,622.67<\/p><\/td> £252,865.56<\/p><\/td><\/tr> Travel<\/p><\/td> £144,122.38<\/p><\/td> £226,600.29<\/p><\/td> £370,722.67<\/p><\/td><\/tr> Subsistence<\/p><\/td> £16,171.73<\/p><\/td> £43,176.88<\/p><\/td> £59,348.61<\/p><\/td><\/tr> Other (incidentals such as printing, room hire and meeting refreshments)<\/p><\/td> £1,939.11<\/p><\/td> £3052.73<\/p><\/td> £4991.84<\/p><\/td><\/tr> Total<\/p><\/td> £244,476.11<\/p><\/td> £443,452.57<\/p><\/td> £687,928.68<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2015-03-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/224723/answer/previousversion/49061", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
}
, "questionFirstAnswered" : [{"_value" : "2015-03-10T17:13:10.723Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-03-17T17:12:17.633Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-03-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mid Staffordshire NHS Foundation Trust"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many consultants have been employed by the Trust Special Administration (TSA) of the Mid-Staffordshire NHS Foundation Trust since its inception; how many person-days they have worked; what (a) accommodation, (b) travel, (c) subsistence and (d) other expenses they have incurred; and what other costs to the TSA they have incurred.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"}
}
, "tablingMemberConstituency" : {"_value" : "Stafford"}
, "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"}
], "uin" : "225962"}
, {"_about" : "http://data.parliament.uk/resources/224727", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/224727/answer", "answerText" : {"_value" : " The Department holds records of the total capital allocated to the respective recipient bodies as a result of the transfer of Mid-Staffordshire NHS Foundation Trust services but does not have details of the breakdown by individual hospital site.<\/p> <\/p> <\/p> <\/p> The capital provided to date is as follows:<\/p> <\/p> <\/p> <\/p> The Royal Wolverhampton NHS Trust<\/p><\/td> £12,109,000<\/p><\/td><\/tr> University Hospitals of North Midlands NHS Trust<\/p><\/td> £12,153,000<\/p><\/td><\/tr> Walsall Healthcare NHS Trust<\/p><\/td> £4,000,000<\/p><\/td><\/tr> Grand Total<\/p><\/td> £28,262,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Revenue funding provided to date is set out in the following table:<\/p> <\/p> <\/p> <\/p> University Hospitals of North Midlands NHS Trust<\/ins><\/p><\/td> £32,420,000<\/p><\/td><\/tr> The Royal Wolverhampton NHS Trust<\/ins><\/p><\/td> £5,480,000<\/p><\/td><\/tr> Grand Total<\/p><\/td> £37,900,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The amount of public dividend capital issued to the Trust by the Department is as follows:<\/p> <\/p> <\/p> <\/p> 2009/10<\/p><\/td> £214,000<\/p><\/td><\/tr> 2010/11<\/p><\/td> £0<\/p><\/td><\/tr> 2011/12<\/p><\/td> £21,000,000<\/p><\/td><\/tr> 2012/13<\/p><\/td> £21,385,000<\/p><\/td><\/tr> 2013/14<\/p><\/td> £30,397,000<\/p><\/td><\/tr> 2014/15<\/p><\/td> £64,425,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The Department does not hold central records of non-tariff payments made by local commissioning bodies to NHS providers.<\/p> <\/p> <\/p> <\/p> The work of the trust special administrators (TSAs) to secure safe and sustainable services at Mid Staffordshire NHS Trust cost Monitor almost £19.5 million, including VAT, over 18 months.<\/p> <\/p> <\/p> <\/p> The first phase of trust special administration cost £9 million, including expenses and VAT. During this phase there was a team of up to 30 members of staff who carried out three core tasks - to help to run the Trust, to design the future of services provided at Stafford and Cannock hospitals, and to run a large public consultation involving thousands of responses and a series of public meetings.<\/p> <\/p> <\/p> <\/p> The second phase cost £10.5 million, including expenses and VAT. We are informed by Monitor that this second phase included a team of up to 50 people, which was required to continue to help run the hospital and implement the TSA\u2019s recommendations.<\/p> <\/p> <\/p> <\/p> We are also informed by Monitor that trust special administration at Mid-Staffordshire NHS Trust amounted to the rounded figure of 10,900 person-days for teams working on both phases of the process.<\/p> <\/p> <\/p> <\/p> In the table below, expenses incurred during the TSA process are split by the two phases of the TSA and totals are also provided. These expenses include:<\/p> <\/p> <\/p> <\/p> (a) accommodation;<\/p> <\/p> (b) travel (car, taxi and train);<\/p> <\/p> (c) subsistence; and<\/p> <\/p> (d) other expenses incurred; and what other costs to the TSA were incurred<\/p> <\/p> <\/p> <\/p> Breakdown of expenses, these exclude VAT:<\/p> <\/p> <\/p> <\/p> TSA1<\/p><\/td> TSA2<\/p><\/td> Total<\/p><\/td><\/tr> Accommodation<\/p><\/td> £82,242.89<\/p><\/td> £170,622.67<\/p><\/td> £252,865.56<\/p><\/td><\/tr> Travel<\/p><\/td> £144,122.38<\/p><\/td> £226,600.29<\/p><\/td> £370,722.67<\/p><\/td><\/tr> Subsistence<\/p><\/td> £16,171.73<\/p><\/td> £43,176.88<\/p><\/td> £59,348.61<\/p><\/td><\/tr> Other (incidentals such as printing, room hire and meeting refreshments)<\/p><\/td> £1,939.11<\/p><\/td> £3052.73<\/p><\/td> £4991.84<\/p><\/td><\/tr> Total<\/p><\/td> £244,476.11<\/p><\/td> £443,452.57<\/p><\/td> £687,928.68<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
, "dateOfAnswer" : {"_value" : "2015-03-10", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/224727/answer/previousversion/49059", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"}
}
, "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"}
}
, "questionFirstAnswered" : [{"_value" : "2015-03-10T17:13:10.44Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-03-17T16:58:03.727Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-03-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Hospitals: West Midlands"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much his Department has provided to implement the recommendations of the Trust Special Administration of Mid-Staffordshire NHS Foundation Trust on (a) capital investment in Stafford Hospital, (b) capital investment in Royal Stoke University Hospital, (c) capital investment in Cannock Hospital, (d) capital investment in New Cross Hospital, (e) other capital investment, (f) revenue support for the University Hospitals of the North Midlands NHS Trust, (g) revenue support for the Royal Wolverhampton Hospitals Trust and (h) other revenue support.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4109", "label" : {"_value" : "Biography information for Jeremy Lefroy"}
}
, "tablingMemberConstituency" : {"_value" : "Stafford"}
, "tablingMemberPrinted" : [{"_value" : "Jeremy Lefroy"}
], "uin" : "226012"}
, {"_about" : "http://data.parliament.uk/resources/224735", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/224735/answer", "answerText" : {"_value" : " Clinical commissioning group (CCG) funding has not been decided beyond 2015/16. Notified revenue allocations and per capita allocations for Cumbria CCG are:<\/p> <\/p> <\/p> <\/p> Year<\/p><\/td> Allocation £000<\/p><\/td> Per capita £<\/p><\/td><\/tr> 2013/14<\/p><\/td> 663,133<\/ins><\/p><\/td> 1,274<\/ins><\/p><\/td><\/tr> 2014/15<\/p><\/td> 677,324<\/p><\/td> 1,299<\/p><\/td><\/tr> 2015/16<\/p><\/td> 685,654<\/p><\/td> 1,313<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> These figures exclude running cost and Better Care Fund allocations.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-03-06", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/224735/answer/previousversion/48371", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2015-03-06T14:39:07.327Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-03-19T18:02:16.817Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-03-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Clinical Commissioning Groups: Cumbria"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what funding (a) in total and (b) per capita has been allocated for Cumbria Clinical Commissioning Group for each year from 2013-14 to 2019-20.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1503", "label" : {"_value" : "Biography information for Mr Jamie Reed"}
}
, "tablingMemberConstituency" : {"_value" : "Copeland"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jamie Reed"}
], "uin" : "226114"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answeringDeptId=17&max-answer.questionFirstMinisteriallyCorrected.=2018-11-20T17%3A09%3A59.22Z&max-date=2015-07-16", "page" : 0, "startIndex" : 1, "totalResults" : 49, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
The BCSH operates independently of Department and NHS England and produces evidence based guidelines for both clinical and laboratory haematologists on the diagnosis and treatment of haematological disease, drawing on the advice of expert consultants and clinical scientists practicing in the United Kingdom. It would be for the BCSH, not the Department, to consider whether any adjustments to current best practice in the diagnosis and treatment of patients with pernicious anaemia were needed, including whether any new or additional tests were appropriate. A copy of the BCSH guidance document has already been placed in the Library and<\/del> is attached.<\/p>
More general clinical guidance on the diagnosis and management of pernicious anaemia can also be found on the National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries website. This is a freely accessible online resource that covers the causes, symptoms, diagnosis and treatment of pernicious anaemia, as well as potential complications of the condition. In addition to this, NHS Choices provides similar, though less technical, information on pernicious anaemia for the public.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/390599/answer/attachment/1", "fileName" : {"_value" : "colbalamin and folate disorders.pdf"}
, "title" : "BCSH Guidelines pernicious anaemia"}
, "dateOfAnswer" : {"_value" : "2015-07-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/390599/answer/previousversion/17459", "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/390599/answer/previousversion/17459/attachment/1", "fileName" : {"_value" : "colbalamin and folate disorders.pdf"}
, "title" : "BCSH Guidelines pernicious anaemia"}
}
, "questionFirstAnswered" : [{"_value" : "2015-07-24T13:21:19.45Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-10-14T11:21:08.233Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Anaemia"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government what action they are taking to address the problems associated with the late diagnosis of pernicious anaemia, in the light of the results of the survey published in the British Nursing Journal<\/i> in April 2014.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
}
, "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
], "uin" : "HL1539"}
, {"_about" : "http://data.parliament.uk/resources/390600", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/390600/answer", "answerText" : {"_value" : "
The BCSH operates independently of Department and NHS England and produces evidence based guidelines for both clinical and laboratory haematologists on the diagnosis and treatment of haematological disease, drawing on the advice of expert consultants and clinical scientists practicing in the United Kingdom. It would be for the BCSH, not the Department, to consider whether any adjustments to current best practice in the diagnosis and treatment of patients with pernicious anaemia were needed, including whether any new or additional tests were appropriate. A copy of the BCSH guidance document has already been placed in the Library and<\/del> is attached.<\/p>
More general clinical guidance on the diagnosis and management of pernicious anaemia can also be found on the National Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries website. This is a freely accessible online resource that covers the causes, symptoms, diagnosis and treatment of pernicious anaemia, as well as potential complications of the condition. In addition to this, NHS Choices provides similar, though less technical, information on pernicious anaemia for the public.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/390600/answer/attachment/1", "fileName" : {"_value" : "colbalamin and folate disorders.pdf"}
, "title" : "BCSH Guidelines pernicious anaemia"}
, "dateOfAnswer" : {"_value" : "2015-07-24", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/390600/answer/previousversion/17460", "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"}
}
, "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"}
, "attachment" : {"_about" : "http://data.parliament.uk/resources/390600/answer/previousversion/17460/attachment/1", "fileName" : {"_value" : "colbalamin and folate disorders.pdf"}
, "title" : "BCSH Guidelines pernicious anaemia"}
}
, "questionFirstAnswered" : [{"_value" : "2015-07-24T13:21:19.357Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-10-14T11:21:19.847Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Anaemia"}
, "houseId" : {"_value" : "2"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
}
], "questionText" : "To ask Her Majesty\u2019s Government how they propose to alert medical practitioners to the severe and irreversible nerve damage that can occur when pernicious anaemia is misdiagnosed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
}
, "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
], "uin" : "HL1540"}
, {"_about" : "http://data.parliament.uk/resources/386702", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/386702/answer", "answerText" : {"_value" : "
2014/15<\/del> of training to become a general practitioner is £485,390 with the consultant training cost being £726,551. These figures reflect the pre-registration costs of tuition, living expenses/lost production and clinical placements and the post-graduate costs of tuition and replacement costs not the average cost to the taxpayer.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3988", "label" : {"_value" : "Biography information for Ben Gummer"}
}
, "answeringMemberConstituency" : {"_value" : "Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Ben Gummer"}
, "dateOfAnswer" : {"_value" : "2015-07-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/386702/answer/previousversion/12875", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3988", "label" : {"_value" : "Biography information for Ben Gummer"}
}
, "answeringMemberConstituency" : {"_value" : "Ipswich"}
, "answeringMemberPrinted" : {"_value" : "Ben Gummer"}
}
, "questionFirstAnswered" : [{"_value" : "2015-07-08T13:27:38.407Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2015-11-02T11:19:49.87Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-06-30", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medicine: Education"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what the average cost to the taxpayer is of training someone to become a doctor in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1200", "label" : {"_value" : "Biography information for Sir Greg Knight"}
}
, "tablingMemberConstituency" : {"_value" : "East Yorkshire"}
, "tablingMemberPrinted" : [{"_value" : "Sir Greg Knight"}
], "uin" : "4761"}
, {"_about" : "http://data.parliament.uk/resources/385301", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/385301/answer", "answerText" : {"_value" : "NHS England and Public Health England (PHE) are working alongside a coalition of other organisations and patient groups to draft a framework for hepatitis C improvement. This hepatitis C improvement framework will set high level aims for the public health system towards elimination of hepatitis C related liver disease as a significant public health concern.<\/del><\/p>The hepatitis C improvement framework will be referred to in PHE\u2019s liver disease framework.<\/del><\/p>and<\/del> £25 million as part of the Prime Minister\u2019s GP Access Fund, over four years to improve premises and information technology, which will also improve access.<\/p>0.78 (0.22)<\/del><\/p><\/td><\/tr>0.18 (0.06)<\/del><\/p><\/td><\/tr>0.06 (0.04)<\/del><\/p><\/td><\/tr>The Royal Wolverhampton NHS Trust<\/del><\/p>University Hospitals of North Midlands NHS Trust<\/del><\/p> <\/td> The Royal Wolverhampton NHS Trust<\/del><\/p>University Hospitals of North Midlands NHS Trust<\/del><\/p> <\/td> The Royal Wolverhampton NHS Trust<\/del><\/p>University Hospitals of North Midlands NHS Trust<\/del><\/p> <\/td> 692,122<\/del><\/p>1,330<\/del><\/p>